Non-Invasive Diagnosis and Monitoring of Cardiac Masses by Liquid Biopsy

Condition(s) studied

Investigational drug(s) / intervention(s)

NGS-guided regimen: Regimen A: Liquid biopsy, consisting of a venous blood sample, will be collected during routine venipuncture

Study summary

This is a nonprofit, observational, prospective and retrospective,multicenter study in a population of young and adult patients ≥12 years with a diagnosis of a cardiac mass. The study will include both patients with masses of unknown pathological diagnosis and patients with a known histology of benign or malignant tumors. We predict a case-control allocation ratio of 1:1 between cardiac malignant tumors and benign lesions. Peripheral blood will be collected at participating centers during routine venipuncture,processed and then shipped for liquid biopsy ctDNA NGS analyses. If available, in malignant cases, matched tumor tissue samples collected as per clinical practice solid biopsies or surgery will be used for analyses. Longitudinal tracking through serial blood draws could be performed in selected cases of patients with cardiac malignancies who receive cancer treatment

Eligibility

Primary outcome measure(s)

• Molecular profile — Jul2024-Jul2029
  Collect and analyse blood and tissue samples from both cases and control in terms of molecular profile

Trial sites (1)

More Niguarda Hospital trials in Italy